Table 1.
Baseline characteristics of the Asian subpopulation and intention‐to‐treat population
| Characteristic | Asian subpopulation (n = 114) | ITT population (N = 1623) | ||||
|---|---|---|---|---|---|---|
| Rd continuous (n = 36) | Rd18 (n = 38) | MPT (n = 40) | Rd continuous (n = 535) | Rd18 (n = 541) | MPT (n = 547) | |
| Median age (range), years | 67·5 (44·0–83·0) | 67·0 (43·0–80·0) | 69·5 (51·0–86·0) | 73·0 (44·0–91·0) | 73·0 (40·0–89·0) | 73·0 (51·0–92·0) |
| ≥65 years, n (%) | 23 (63·9) | 26 (68·4) | 30 (75·0) | 504 (94·2) | 507 (93·7) | 520 (95·1) |
| Male, n (%) | 23 (63·9) | 23 (60·5) | 20 (50·0) | 294 (55·0) | 273 (50·5) | 287 (52·5) |
| ISS stage, n (%) | ||||||
| I/II | 21 (58·3) | 20 (52·6) | 22 (55·0) | 319 (59·6) | 322 (59·5) | 323 (59·0) |
| III | 15 (41·7) | 18 (47·4) | 18 (45·0) | 216 (40·4) | 219 (40·5) | 224 (41·0) |
| CrCl, n (%) | ||||||
| <30 ml/min | 3 (8·3) | 9 (23·7) | 9 (22·5) | 45 (8·4) | 47 (8·7) | 55 (10·1) |
| ≥30–50 ml/min | 3 (8·3) | 9 (23·7) | 5 (12·5) | 126 (23·6) | 120 (22·2) | 126 (23·0) |
| ≥50 ml/min | 30 (83·3) | 20 (52·6) | 26 (65·0) | 364 (68·0) | 374 (69·1) | 366 (66·9) |
| ECOG PS, n (%) | ||||||
| 0 | 4 (11·1) | 7 (18·4) | 5 (12·5) | 155 (29·0) | 163 (30·1) | 156 (28·5) |
| 1 | 22 (61·1) | 20 (52·6) | 24 (60·0) | 257 (48·0) | 263 (48·6) | 275 (50·3) |
| 2 | 10 (27·8) | 11 (28·9) | 11 (27·5) | 119 (22·2) | 113 (20·9) | 111 (20·3) |
| ≥3 | 0 | 0 | 0 | 2 (0·4) | 2 (0·4) | 2 (0·4) |
| Missing | 0 | 0 | 0 | 2 (0·4) | 0 | 3 (0·5) |
CrCl, creatinine clearance; ECOG PS, Eastern Cooperative Oncology Group performance score; ISS, International Staging System; ITT, intention‐to‐treat; MPT, melphalan, prednisone, thalidomide; Rd continuous, lenalidomide plus low‐dose dexamethasone until disease progression; Rd18, lenalidomide plus low‐dose dexamethasone for 18 cycles.